case_images: PMC11032179_01
case_images: Vaginal cancer photomicrographs. a Immunohistochemical detection of p40 which resulted in its expression. b Immunohistochemical detection of p16 which was not expressed at a x20 magnification. c Hematoxylin-eosin immunohistochemistry of a section of SCC at a x10 magnification.
case_images: cro-2024-0017-0001-535041_F01.jpg
case_images: PMC11032179_01_cro-2024-0017-0001-535041_F01.jpg
case_images: F1
case_images: The cancer grading was not specified (Fig. 1a-c).
case_images: PET/CT evaluations from the start of pembrolizumab. a Baseline PET/CT (December 2021), before the start of ICI therapy. b Metabolic partial response after 3 months of ICI therapy (April 2022). c Further metabolic response after 3 months of ICI therapy (July 2022).
case_images: cro-2024-0017-0001-535041_F02.jpg
case_images: PMC11032179_01_cro-2024-0017-0001-535041_F02.jpg
case_images: F2
case_images: After 2 months, the patient complained of worsening inguinal pain that affected her walking capability, and the 18F-FDG PET/CT showed a dimensional increase of right inguinal lymph nodes (SUVmax 12.9) (Fig. 2a). In April 2022, an 18F-FDG PET/CT highlighted an initial size reduction of the nodal recurrence, with a slight increase of the uptake (SUVmax 13.8), probably due to the inflammatory process (Fig. 2b). In July 2022, the 18F-FDG PET/CT showed further reduction both in size and in metabolic activity of the right inguinal mass (SUVmax 7.7) (Fig. 2c).
case_images: Clinical presentation of the right inguinal mass in April 2022 (a) and in July 2022 (b).
case_images: cro-2024-0017-0001-535041_F03.jpg
case_images: PMC11032179_01_cro-2024-0017-0001-535041_F03.jpg
case_images: F3
case_images: In April 2022, the inguinal mass started to produce abundant blood serum fluid (Fig. 3a). The smaller diameter of the mass was clinically evident, with softer and clearer overlying skin (Fig. 3b).